Shares in Sirtex Medical jumped after the liver cancer treatment group announced a better than expected lift in earnings.
A short time ago, the shares were up 12.%% to $17.61.
The company said EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) for the six months to December is expected to be to about $34 million, up 16% growth on the same six months last year.
CEO Andrew McLean says he anticipate higher sales in the second half, resulting in full year EBITDA in the range of $75 million to $85 million. This compares to an underlying EBITDA of $61.5 million in the 2017 financial year.
Sirtex makes radioactive spheres to treat liver cancer.